Cardiac β-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury: Evidence for catecholamine-mediated myocardial damage

Circulation

Volumn 92, Issue 8, 1995, Pages 2183-2189

  White, Michel ^b   Wiechmann, Robert J ^b   Roden, Robert L ^b   Hagan, Mary Beth ^b   Wollmering, Mary M ^b   Port, J David ^b   Hammond, Elizabeth ^b   Abraham, William T ^b   Wolfel, Eugene E ^b   Lindenfeld, JoAnn ^b   Fullerton, David ^b   Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

catecholamines; heart failure; proteins; receptors, adrenergic, beta

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ACUTE HEART INFARCTION; ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ARTICLE; BRAIN INJURY; CATECHOLAMINE RELEASE; ENZYME INHIBITION; GENE EXPRESSION; HEART FAILURE; HEART MUSCLE CELL; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL;

EID: 0028972891     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.92.8.2183     Document Type: Article

References (37)

1. Kriett JM, Kaye MP. The registry of the International Society for Heart and Lung Transplantation: eighth official report: 1991. J Heart Lung Transplant. 1991;10:491-498.
2. Stevenson LW, Warner SL, Steimle AE, Fonarow GC, Hamilton MA. Moriguchi JD, Kobashigawa JA, Tillisch JH, Drinkwater DC, Laks H. The impending crisis awaiting cardiac transplantation: modeling a solution based on selection. Circulation. 1994;89: 450-457.
3. Gilbert EM, Krueger SK, Murray JL, Renlund DG, O'Connell JB, Gay WA, Bristow MR. Echocardiographic evaluation of potential cardiac donors. J Thorac Cardiovasc Surg. 1988;95:1003-1007.
4. Wiechmann RJ, Eastburn T, Murray J, Port JD, O'Connell JB, Renlund DG, Hershberger RE, Bristow MR. Cardiac donor heart dysfunction: evidence for catecholamine-mediated myocardial injury. J Am Coll Cardiol. 1990;15:84A. Abstract.
5. Brackett CE. Systemic complications of central nervous system trauma. In: Odom GL, ed. Central Nervous System Trauma Research Status Report, 1979. Washington, DC: Public Health Service; 1979: 232-263.
6. Woolf PD, Hamill RW, Lee LA, Cox C, McDonald JV. The predictive value of catecholamines in assessing outcome in traumatic brain injury. J Neurosurg. 1987;66:872-882.
7. Evans JP, Espey FF, Kristoff FV, Kimbell FD, Ryder HW. Experimental and clinical observations on rising intracranial pressure. Arch Surg. 1951;63:107-114.
8. Shanlin RJ, Sole MJ, Rahimfar M, Tator CH, Factor SM. Increased intracranial pressure elicits hypertension, increased sympathetic activity, electrocardiographic abnormalities and myocardial damage in rats. J Am Coll Cardiol. 1988;12:727-736.
9. Shivalkar B, Van Loon J, Wieland W, Tjandra-Maga TB, Borgers M, Plets C, Flameng W. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation. 1993;87:230-239.
10. Bobik A, Campbell JH, Carson V, Campbell GR. Mechanism of isoprenaline-induced refractoriness of the β-adrenoceptor-adenylate cyclase system in chick embryo cardiac cells. J Cardiovasc Pharmacol. 1981;3:541-553.
11. 1 adrenoceptor desensitization in mammalian cardiac myocytes. Cardiovasc Res. 1986;20:221-228.
12. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
13. Patel MB, Stewart JM, Loud AV, Anversa P, Wang J, Feigel L, Hintze TH. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation. 1991;84: 2091-2100.
14. Vatner DE, Vatner SF, Nejima J, Uemura N, Susanni EE, Hintze TH, Homey CJ. Chronic norepinephrine elicits desensitization by uncoupling the β-receptor. J Clin Invest. 1989;84:1741-1748.
15. Lee JC, Downing SE. Ventricular function in norepinephrine-induced cardiomyopathic rabbits. Am J Physiol. 1982;242:H191-H196.
16. 1-receptor mRNA abundance in the failing human heart. J Clin Invest. 1993;92:2737-2745.
17. 1-receptor down-regulation in heart failure. Circ Res. 1986;59:297-309.
18. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, Feldman AM. Differences in β-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:1024-1039.
19. Salomon Y, Londos C, Rodhell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 1974;58:541-548.
20. Peterson GL. A simplification of the protein assay method of Lowry, et al, which is more generally applicable. Ann Biochem. 1977;83:346-356.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the phenol reagent. J Biol Chem. 1951;193:265-275.
22. Nanoff C, Freissmuth M, Tuisl E, Schütz W. A different desensitization pattern of cardiac β-adrenoceptor subtypes by prolonged in vivo infusion of isoprenaline. J Cardiovasc Pharmacol. 1989;13: 198-203.
23. Molenaar P, Smolich JJ, Russell FD, McMartin LR, Summers RJ. Differential regulation of beta-1 and beta-2 adrenoceptors in guinea pig atrioventricular conducting system after chronic (-)-isoproterenol infusion. J Pharmacol Exp Ther. 1990;255:393-400.
24. Anderson FL, Port JD, Reid BB, Hanson G, Kralios A, Hershberger RE, Bristow MR. Effect of therapeutic dopamine administration on myocardial catecholamines and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 1992;20:800-806.
25. Gilbert EM, Larrabee P, Volkman K, Mealey PC, Renlund DG, Olsen SL, Bristow MR. Does dobutamine tolerance result from myocardial β-receptor down-regulation? J Am Coll Cardiol. 1992; 19:253A. Abstract.
26. White M, Roden RL, Minobe W, Khan MF, Larrabee P, Wollmering M, Port JD, Anderson F, Campbell D, Feldman AM, Bristow MR. Age-related changes in β-adrenergic neuroeffector systems in the human heart. Circulation. 1994;90:1225-1238.
27. Strittmutter S, Neer EJ. Properties of the separated catalytic and regulatory units of brain adenylyl cyclase. Proc Natl Acad Sci U S A. 1980;77:6344-6348.
28. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, Van Dop C. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest. 1988;82:189-197.
29. Furuyama M, Haneda T, Ikeda J, Hiramoto T, Sakuma T, Kanda H, Shirato K, Takishima T. Responses of atrium and ventricle to sustained sympathetic nerve stimulation. Am J Physiol. 1991;261: H1889-H1894.
30. Pilati CF, Clark RS, Gilloteaux J, Bosso FJ, Holcomb P, Maron MB. Excessive sympathetic nervous system activity decreases myocardial contractility. Proc Soc Exp Biol Med. 1990;193:225-231.
31. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, Fowler M, Ginsburg R. β-Adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992;89:803-815.
32. Galinanes M, Hearse DJ. Brain death-induced impairment of cardiac contractile performance can he reversed by explantation and may not preclude the use of hearts for transplantation. Circ Res. 1992;71:1213-1219.
33. 1-selective blockade. Lancet. 1987;2:585-589.
34. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
35. Beta-Blocker Heart Attack Study Group. The Beta-Blocker Heart Attack Trial. JAMA. 1981;246:2073-2074.
36. Port JD, Gilbert EM, Larrabee P, Mealey P, Volkman K, Ginsburg R, Hershberger RE, Murray J, Bristow MR. Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation. 1990;81:929-938.
37. Powner DJ, Hendrich A, Nyhuis A, Strate R. Changes in serum catecholamine levels in patients who are brain dead. J Heart Lung Transplant. 1992;11:1046-1053.